Campath G Clinical Trials

All Categories Medications / Interventions » Cc » Campath G

Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation

Conditions: Myeloid Malignancy; Bone Marrow Failure Syndrome; Transfusion-dependent Red Blood Cell (RBC) Defect; Congenital Immunodeficiency; Metabolic Disease; Severe Immune Dysregulation
Interventions: Drug: Alemtuzumab; Drug: Busulfan; Drug: Fludarabine; Drug: Clofarabine
Sponsors: University of California, San Francisco; Christopher Dvorak
Not yet recruiting - verified May 2012
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)

Conditions: Leukemia; Lymphoma; Myeloma; Myeloproliferative Diseases
Interventions: Drug: Fludarabine; Drug: Melphalan; Drug: Alemtuzumab; Procedure: Stem Cell Infusion; Drug: Tacrolimus; Drug: Methotrexate; Drug: G-CSF; Procedure: Low Dose Donor T-Cells; Procedure: High Dose Donor T-Cells
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Study of Allogeneic Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

Condition: Sickle Cell Disease
Interventions: Procedure: Allogeneic Non-Myeloablative Stem Cell Transplantation; Drug: Alemtuzumab; Drug: Sirolimus
Sponsors: University of Illinois; University of Illinois
Recruiting - verified November 2011
Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL

Conditions: CLL; SLL
Interventions: Drug: Ofatumumab; Drug: High-Dose Methylprednisolone; Drug: Alemtuzumab
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; National Comprehensive Cancer Network; GlaxoSmithKline
Recruiting - verified December 2011
Optimization of NULOJIX® (Belatacept) Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation

Condition: Kidney Transplantation
Interventions: Drug: Alemtuzumab induction; MMF + Tacrolimus maintenance; Drug: Alemtuzumab induction; MMF + Belatacept maintenance; Drug: Basiliximab induction; Short-term (3 months)Tacrolimus; MMF + Belatacept maintenance
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011
Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

Conditions: Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia
Interventions: Biological: alemtuzumab; Biological: ofatumumab; Procedure: biopsy
Sponsors: Northwestern University; Northwestern University; GlaxoSmithKline; National Comprehensive Cancer Network
Recruiting - verified August 2011
Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia

Conditions: B-cell Chronic Lymphocytic Leukemia; Refractory Chronic Lymphocytic Leukemia; Stage 0 Chronic Lymphocytic Leukemia; Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia
Interventions: Biological: alemtuzumab; Biological: rituximab; Drug: PGG beta-glucan; Other: flow cytometry; Other: laboratory biomarker analysis; Genetic: DNA analysis; Genetic: fluorescence in situ hybridization; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Genetic: mutation analysis
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified April 2012
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: alemtuzumab; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide phosphate; Drug: fludarabine phosphate; Drug: leucovorin calcium; Drug: melphalan; Drug: mercaptopurine; Drug: methotrexate; Drug: vincristine sulfate; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified April 2012
Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)

Condition: Leukemia
Intervention: Drug: Alemtuzumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders

Conditions: Mucopolysaccharidosis; Hurler Syndrome; Hunter Syndrome; Maroteaux-Lamy Syndrome; Sly Syndrome; Alpha Mannosidosis; Fucosidosis; Aspartylglucosaminuria; Adrenoleukodystrophy (ALD); Globoid Cell Leukodystrophy (GLD); Krabbe Disease; Metachromatic Leukodystrophy (MLD); Sphingolipidoses; Peroxisomal Disorders
Interventions: Drug: Campath-1H; Drug: Cyclophosphamide; Drug: Busulfan; Procedure: Allogeneic stem cell transplantation
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas

Conditions: Hodgkin Lymphoma; Diffuse Large B-Cell Lymphoma
Interventions: Drug: Cylcophosphamide; Drug: Etoposide; Drug: Alemtuzumab; Drug: Doxorubicin; Drug: Prednisone; Drug: Filgrastim; Drug: Rituximab; Drug: Vincristine
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified May 2012
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia

Condition: Leukemia
Interventions: Biological: alemtuzumab; Biological: rituximab
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia

Conditions: Peripheral Blood Stem Cell Transplantation; Anemia, Sickle Cell; Graft-Versus-Host Disease; Sirolimus (Rapamune(Registered Trademark)); Alemtuzumab (Campath(Registered Trademark))
Interventions: Procedure: PBMC Transplant; Drug: Alemtuzumab (Campath(Registered Trademark)); Drug: Sirolimus (Rapamune(Registered Trademark)); Drug: Cyclophosphamide (Cytoxan(Registered Trademark)); Procedure: Low Dose Irradiation
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2011
Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Condition: Lymphocytic Leukemia
Interventions: Drug: alemtuzumab; Drug: everolimus
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified April 2012
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

Conditions: Metabolic Disorders; Hematologic, Immune, or Bone Marrow Disorders; Hemoglobinopathies
Interventions: Drug: Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan; Drug: Transplant conditioning regimen of hydroxyurea, campath, fludarabine, thiotepa, & melphalan; Drug: Transplant conditioning regimen of hydroxyurea, campath, fludarabine, thiotepa, & melphalan; Drug: Transplant conditioning regimen of hydroxyurea, campath, fludarabine, thiotepa, & melphalan
Sponsors: Washington University School of Medicine; Washington University School of Medicine; St. Louis Children's Hospital
Recruiting - verified June 2011
Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disease

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Precancerous Condition
Interventions: Biological: alemtuzumab; Drug: busulfan; Drug: fludarabine phosphate; Drug: tacrolimus; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: National Cancer Institute (NCI); Baylor College of Medicine
Recruiting - verified June 2009
Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis

Condition: Histiocytosis, Langerhans-cell
Interventions: Biological: alemtuzumab; Drug: fludarabine phosphate; Drug: melphalan; Procedure: stem cell transplantation
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified November 2011
HLA-Identical Sibling Renal Transplant Tolerance With Donor Hematopoietic Stem Cells and Campath-1H

Conditions: Immunosuppression; Kidney Transplantation; Graft Rejection
Intervention: Procedure: Infusion of Donor Hematopoietic Stem Cells and Campath-1H
Sponsors: Northwestern University; Northwestern University; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified November 2011
Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant

Conditions: Hodgkin's Disease; Non Hodgkin's Lymphoma; Myeloma; Leukemia; Myelodysplasia
Intervention: Drug: Non-myeloablative Stem Cell Transplantation
Sponsors: Duke University; Duke University
Recruiting - verified February 2012
Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease

Condition: Chronic Granulomatous Disease
Interventions: Drug: Busulfan; Biological: alemtuzumab; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: cyclosporine; Procedure: stem cell infusion
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital
Recruiting - verified May 2012
Allogeneic Bone Marrow Transplantation From HLA Identical Related Donors for Patients With Hemoglobinopathies

Conditions: Sickle Cell Disease; Hemoglobin SC
Interventions: Procedure: ALLOGENEIC BMT/SCT Infusion; Drug: Busulfan; Biological: Campath 1H; Drug: Cyclophosphamide and Mesna
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital; The Methodist Hospital System
Recruiting - verified May 2012
T-Reg Cell Kinetics for Patients Receiving Stem Cell Transplant

Conditions: Leukemia; Hodgkin Lymphoma; Non Hodgkin Lymphoma; Myeloproliferative Disorders
Interventions: Drug: Ara C; Drug: Cyclophosphamide; Drug: MESNA; Procedure: TBI; Biological: Campath-1h; Procedure: Stem Cell Infusion; Drug: Tacrolimus; Drug: Methotrexate
Sponsors: Baylor College of Medicine; Baylor College of Medicine
Recruiting - verified April 2012
Stem Cell Transplant in Patients With Thalassemia

Condition: Thalassemia
Interventions: Drug: Busulfan; Drug: Fludarabine; Drug: Campath 1H; Drug: Cyclophosphamide; Drug: MESNA; Procedure: Bone marrow or stem cell infusion
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital
Recruiting - verified May 2012
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies

Conditions: Leukemia, Acute Lymphocytic (ALL); Leukemia, Myeloid, Acute(AML); Leukemia, Myeloid, Chronic(CML); Juvenile Myelomonocytic Leukemia (JMML); Hemoglobinuria, Paroxysmal Nocturnal (PNH); Hodgkin Lymphoma; Lymphoma, Non-Hodgkin (NHL); Myelodysplastic Syndrome (MDS)
Interventions: Device: CliniMACS; Procedure: Stem cell transplantation; Drug: Systemic chemotherapy and antibodies
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified April 2012
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed By a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders

Condition: Precancerous Condition
Interventions: Biological: alemtuzumab; Drug: fludarabine phosphate; Radiation: low dose total-body irradiation; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: allogeneic bone marrow transplantation; Procedure: allogeneic hematopoietic cell transplantation; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System

Conditions: Myelodysplastic Syndrome; Hodgkin's Lymphoma; Non-Hodgkin's Disease; Acute Leukemia; Multiple Myeloma
Interventions: Drug: Cyclophosphamide; Biological: rituximab; Drug: Methotrexate; Drug: Sirolimus; Drug: Cyclosporine; Drug: Doxorubicin hydrochloride; Drug: Etoposide; Drug: Fludarabine phosphate; Drug: Prednisone; Drug: Vincristine sulfate; Drug: Cytarabine; Drug: Tacrolimus; Biological: Alemtuzumab
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified June 2011
SCT for Dyskeratosis Congenita or SAA

Conditions: Dyskeratosis Congenita; Aplastic Anemia
Interventions: Drug: Campath 1H; Drug: Cyclophosphamide; Drug: Fludarabine; Procedure: Total Body Irradiation; Procedure: Stem Cell Transplantation; Drug: ATG
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2012
Donor Stem Cell Transplantation for Congenital Immunodeficiencies

Conditions: MUD Transplant; AlloPBSC; Congenital Immunodeficiencies; HLA Matched Transplant; BMT
Interventions: Drug: Busulfan; Drug: Campath-1 H; Drug: Sirolimus; Procedure: BMT; Procedure: Apheresis; Procedure: Total Body Irradiation; Procedure: GCSF Injections
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012
Stem Cell Transplant in Sickle Cell Disease and Thalassemia

Conditions: Sickle Cell Disease; Beta Thalassemia
Interventions: Drug: Busulfan; Drug: Fludarabine; Drug: Alemtuzumab; Procedure: Allogeneic stem cell transplant
Sponsors: Columbia University; Columbia University
Recruiting - verified October 2011
Alemtuzumab (Campath(Registered Trademark)) to Treat T-Large Granular Lymphocyte Leukemia

Condition: Lymphoproliferative Disorders
Intervention: Drug: Alemtuzumab (Campath)
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2012
A Study to Lower the Occurrences and Severity of Graft-versus-host Disease

Condition: Graft vs Host Disease
Interventions: Drug: Ara-C; Drug: Cyclophosphamide; Drug: MESNA; Drug: Campath-1H; Procedure: Total Body Irradiation; Procedure: Stem cell infusion
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital; The Methodist Hospital System
Recruiting - verified April 2012
A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome

Condition: Myelodysplastic Syndromes
Intervention: Drug: Alemtuzumab (Campath)
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012
Alemtuzumab to Treat Severe Aplastic Anemia

Conditions: Relapsed or Refractory Severe Aplastic Anemia; Severe Aplastic Anemia
Intervention: Drug: Alemtuzumab (Campath(Registered Trademark))
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012
Stem Cell Transplant for Immunologic or Histiocytic Disorders

Conditions: Hemophagocytic Lymphohistiocytosis; X-Linked Lymphoproliferative Disorders; Chediak-Higashi Syndrome; Griscelli Syndrome; Immunologic Deficiency Syndromes; Langerhans-Cell Histiocytosis
Interventions: Procedure: Stem Cell Transplant; Drug: Fludarabine, melphalan, ATG or Campath
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012
Stem Cell Transplant for Hemoglobinopathy

Conditions: Sickle Cell Disease; Thalassemia; Severe Congenital Neutropenia; Diamond-Blackfan Anemia; Shwachman-Diamond Syndrome
Interventions: Drug: Busulfan, Fludarabine, ATG, TLI; Drug: Busulfan, Cyclophosphamide, ATG, GCSF; Drug: Campath, Fludarabine, Cyclophosphamide; Radiation: Total Body Irradiation; Procedure: Stem cell infusion
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota; National Marrow Donor Program
Recruiting - verified April 2012
Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias

Conditions: Congenital Hemolytic Anemia; Diamond-Blackfan Anemia
Interventions: Procedure: Radiotherapy; Drug: Alemtuzumab (Campath(Registered Trademark)); Drug: Sirolimus (Rapamune(Registered Trademark))
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified December 2011
Stem Cell Transplant for Hematologic Diseases

Condition: Hematologic Malignancies
Interventions: Biological: Campath 1H; Drug: Fludarabine; Procedure: Stem Cell Transplant; Radiation: TBI
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital; The Methodist Hospital System
Recruiting - verified April 2012